Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
Date:10/29/2009

Gastroenterologie, Hepatologie und Infektiologie, Heinrich-Heine-Universitat Dusseldorf, Dusseldorf, Germany
  • Tuesday, November 3, 2009, 8:00 a.m. - 1:00 p.m., Exhibit Hall C
  • Abstract #1675
  • Efficacy and Safety of Sorafenib in Patients from the Asia-Pacific (AP) Region with Advanced Hepatocellular Carcinoma (HCC): Impact of Prior Transarterial Chemoembolization and Transarterial Embolization (TACE/TAE)

    • Dr. Zhendong Chen, First Affiliated Hospital of Anhui Medical University, Hefei, China
    • Tuesday, November 3, 2009, 8:00 a.m. - 1:00 p.m., Exhibit Hall C
    • Abstract #1694

    "Liver cancer is often diagnosed at an advanced stage when patients tend to be very ill due to pre-existing liver disease," said Todd Yancey, M.D., vice president of clinical development at Onyx. "Onyx and Bayer are committed to evaluating Nexavar in ongoing studies, as will be presented at AASLD, in order to realize the potential benefit the therapy may offer to patients at all stages of the disease and in different treatment settings."

    Nexavar's Differentiated Mechanism

    Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, c-FLT-3 and RET.

    Nexavar is currently approved in more than 80 countries for the treatment of patients with liver cancer and in more than 90 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including breast cancer,
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
    2. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
    5. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
    6. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    7. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
    8. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
    9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
    10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
    11. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
    (Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
    (Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
    Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
    ... 2011 The American Association for Homecare strongly endorses ... Medicare "competitive" bidding program for home medical equipment and ... introduced by Congressmen Glenn Thompson (R-Pa.) and Jason Altmire ... "Fairness in Medicare Bidding Act."   ...
    ... 2011 AstraZeneca today announced enrolment of the first ... an oral peripherally-acting opioid antagonist being investigated for the ... programme is designed to investigate the safety and efficacy ... constipation, a common side effect of prescription opioids when ...
    Cached Medicine Technology:Home Medical Equipment Group Supports Bipartisan Bill to Repeal the Controversial Medicare 'Competitive' Bidding Program for Homecare 2Home Medical Equipment Group Supports Bipartisan Bill to Repeal the Controversial Medicare 'Competitive' Bidding Program for Homecare 3AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation 2AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation 3
    (Date:4/24/2014)... professor in the new Institute for Biomedical Sciences ... $2.83 million federal grant to develop novel therapeutics ... grant from the Eunice Kennedy Shriver National Institute ... National Institutes of Health will support Plemper,s drug ... at least one distinct alternative compound. , Infections ...
    (Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
    (Date:4/24/2014)... was the first in the world to discover a ... the jaw. , Ameloblastoma is an odontogenic tumour with ... most often found in the posterior of the lower ... tissue deficiencies in the jaws as well as loss ... the need for surgery and the recurrence of ameloblastoma, ...
    (Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
    (Date:4/23/2014)... General Hospital (MGH) investigators may lead to greater availability ... medical problem use of fecal material from healthy ... Clostridium difficile ( C. difficile ) bacteria. ... Clinical Infectious Diseases , the researchers report that ... to patients was as successful in curing recurrent ...
    Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
    ... This release is available in German . ... and learning about the warning signs of lymphedema: that,s ... lymphedema, according to the German Institute for Quality and ... about how to protect themselves from this common and ...
    ... AUGUSTA, Maine, Nov. 6 Building on the ... for small businesses in Maine,the Maine State Chamber ... and Blue Shield have announced further additions to ... January, Chamber,BlueOptions will include eight health plans from ...
    ... Invisicare Is Put In Place, LAS VEGAS, ... the developers of Invisicare, a patented polymer,delivery system ... of Geert Cauwenbergh, PhD to head its International,Advisory ... expand the demand,for Invisicare in international markets. Dr. ...
    ... Nov. 6 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., (Amex: ... traditional Chinese medicine ("TCM") based in Chengdu, China,today ... to discuss its,2009 fiscal first quarter at 8:30 ... will be released that day before the market ...
    ... A steady march toward using,ever-more "patient-friendly" ... proceedings of the 37th Global Congress of ... international professional society for,specialists in minimally invasive ... preserving the highest possible quality of,life for ...
    ... People With,Diabetes and Their Caregivers, WESTPORT, Conn., Nov. ... laughter, and family, usually accompanied by trays of cookies,cakes, ... some,of the nearly 24 million people in America with ... dLife helped over 100,000 online,visitors survive the season with ...
    Cached Medicine News:Health News:How women can improve their quality of life after breast cancer treatment 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 3Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 4Health News:Back By Popular Demand - dLife Holiday Helpline 2
    ... System 9700 can now be used with ... The aluminum block has been designed for ... sequencing in a conventional 8 X 12 ... system to be used in 9600 emulation ...
    96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
    ... for day-to-day temperature cycling ... 0.1C ,30% reduction in ... or coolant-based cyclers ,4 ... ramping ,Options for oil-free ...
    ... TC-512 has a graphical touch screen display ... at the "touch of a screen." ... gradient, Touch Screen, Graphical Display, Memory Cards, ... Block Format, Intuitive Programmin, Free Instrument Software ...
    Medicine Products: